Biocept Selector Liquid Biopsy for Non-Small Cell Lung Cancer

Biocept announced it has launched a blood-based EGFR mutation test for non-small cell lung cancer patients based on its Selector technology platform. Screening circulating tumor cells and DNA, the assay targets a region of the gene that includes T790M, a biomarker that identifies therapy-resistant tumors. This test will be performed at the firm's CLIA-certified and CAP-accredited laboratory.